ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Estradiol Inhibits Certain Inflammatory Activation of C-Reactive Protein
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="CoastWatcher" data-source="post: 95101" data-attributes="member: 2624"><p>Cardiovascular disease (CVD) is currently the most important cause of death in developed countries.</p><p></p><p>[ATTACH]4576[/ATTACH]</p><p></p><ul> <li data-xf-list-type="ul"> Atherosclerosis, the underlying cause of most CVDs, is a dynamic and progressive inflammatory disease characterized by lipid plaque formation within the arterial wall and luminal reduction. In fact, accumulating</li> <li data-xf-list-type="ul">Data suggests that the inflammatory process plays a central role in the initiation, progression, and the final steps of this pathology as vulnerable plaque rupture.</li> <li data-xf-list-type="ul">The C-reactive protein (CRP) has emerged as the most powerful predictor and is an extensively studied systemic marker of inflammation of high sensitive CRP (hsCRP) correlates with the risk of future atherosclerotic events.</li> <li data-xf-list-type="ul">This plasmatic protein synthesized by hepatocytes in response to inflammation and tissue injury induces pro-inflammatory molecules' expression by endothelial cells (ECs).</li> <li data-xf-list-type="ul"><strong>Previous studies showed that the 17&#946;-estradiol (E2) has beneficial effects on vascular cells by reducing in vitro pro-inflammatory molecules expressions in EC.</strong> <strong>It is hypothesized that E2 blocks or reduces CRP-mediated inflammatory responses by modulating endogenous production of CRP in EC and/or activation mechanisms.</strong></li> <li data-xf-list-type="ul"><strong>A 1-h pre-treatment of E2 at a physiologic dose (10[SUP]<span style="font-size: 10px">&#8722;9 </span>[/SUP]M) leads to an important decrease of CRP production suggesting a partial blockage of its amplification loop mechanism. </strong></li> <li data-xf-list-type="ul"><strong>Furthermore, in HAEC, E2 reduces the secretion of the most potent agonist of CRP induction, the IL-6, by 21 %. E2 pre-treatment also decreased the expression of pro-inflammatory molecules IL-8, VCAM-1, and ICAM-1 induced by CRP and involved in leukocytes recruitment</strong>.</li> <li data-xf-list-type="ul"><strong>In addition, we demonstrated that E2 could restore vascular endothelial growth factor-mediated EC migration response impaired by CRP suggesting another pro-angiogenic property of this hormone.</strong></li> </ul><p></p><p></p><p>"Estradiol inhibits vascular endothelial cells pro-inflammatory activation induced by C-reactive protein," <em>Journal of Molecular and Cellular Cardiology, </em>2004 March, <a href="https://www.ncbi.nlm.nih.gov/pubmed/23111890" target="_blank">https://www.ncbi.nlm.nih.gov/pubmed/23111890</a></p></blockquote><p></p>
[QUOTE="CoastWatcher, post: 95101, member: 2624"] Cardiovascular disease (CVD) is currently the most important cause of death in developed countries. [ATTACH=CONFIG]4576[/ATTACH] [LIST] [*] Atherosclerosis, the underlying cause of most CVDs, is a dynamic and progressive inflammatory disease characterized by lipid plaque formation within the arterial wall and luminal reduction. In fact, accumulating [*]Data suggests that the inflammatory process plays a central role in the initiation, progression, and the final steps of this pathology as vulnerable plaque rupture. [*]The C-reactive protein (CRP) has emerged as the most powerful predictor and is an extensively studied systemic marker of inflammation of high sensitive CRP (hsCRP) correlates with the risk of future atherosclerotic events. [*]This plasmatic protein synthesized by hepatocytes in response to inflammation and tissue injury induces pro-inflammatory molecules' expression by endothelial cells (ECs). [*][B]Previous studies showed that the 17β-estradiol (E2) has beneficial effects on vascular cells by reducing in vitro pro-inflammatory molecules expressions in EC.[/B] [B]It is hypothesized that E2 blocks or reduces CRP-mediated inflammatory responses by modulating endogenous production of CRP in EC and/or activation mechanisms.[/B] [*][B]A 1-h pre-treatment of E2 at a physiologic dose (10[SUP][SIZE=2]−9 [/SIZE][/SUP]M) leads to an important decrease of CRP production suggesting a partial blockage of its amplification loop mechanism. [/B] [*][B]Furthermore, in HAEC, E2 reduces the secretion of the most potent agonist of CRP induction, the IL-6, by 21 %. E2 pre-treatment also decreased the expression of pro-inflammatory molecules IL-8, VCAM-1, and ICAM-1 induced by CRP and involved in leukocytes recruitment[/B]. [*][B]In addition, we demonstrated that E2 could restore vascular endothelial growth factor-mediated EC migration response impaired by CRP suggesting another pro-angiogenic property of this hormone.[/B] [/LIST] "Estradiol inhibits vascular endothelial cells pro-inflammatory activation induced by C-reactive protein," [I]Journal of Molecular and Cellular Cardiology, [/I]2004 March, [URL]https://www.ncbi.nlm.nih.gov/pubmed/23111890[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Estradiol Inhibits Certain Inflammatory Activation of C-Reactive Protein
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top